ADAR1 Partners, LP's Form 4 filing
Keros Therapeutics, Inc. (KROS) · filed Oct 15, 2025
- Accession no.
- 0000902664-25-004411
- Filed
- Oct 15, 2025, 1:24 PM ET
- Trade date
- Oct 15, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $95.7M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| ADAR1 Partners, LPCIK 0001758866 | 10% Owner |
| Schneeberger DanielCIK 0001861120 | 10% Owner |
| ADAR1 Capital Management GP, LLCCIK 0001940267 | 10% Owner |
| ADAR1 Capital Management, LLCCIK 0001940272 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | Common Stock | SSaleDisposed | −4,391,237 | $17.75 | −$77,944,456.75 | 0 | Indirect | |
| Oct 15, 2025 | Common Stock | SSaleDisposed | −254,669 | $17.75 | −$4,520,374.75 | 0 | Indirect | |
| Oct 15, 2025 | Common Stock | SSaleDisposed | −743,358 | $17.75 | −$13,194,604.5 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.